Gyg Share Discussion Threads

[maddox] 24/3/2006 19:17

The shares have come off a bit 10.5% at the lowest recent point (378p). This looks like some profit taking after a very strong run - at 385p GYG are still about 46% up on a year ago.

More importantly there appears to be no reason to sell. The top-line figures obscure a very strong underlying performance. The old Gyrus business achieved 15% yoy and ACMI 6.5%, this despite the merger integration. With savings still to be made and business synergy benefits yet to show through the auspices are good. Then there are the new products on the way this year and further geographic expansion.

Also, as the reported figs are depressed by the IFRS reporting requirements - the next few periods should produce some excellent looking results. With the only negative, the patent dispute with Medtronic, the outlook looks pretty good. But as always DYOR.

Regards, Maddox

[rochdae] 22/3/2006 11:33

Strange reaction to a great set of results. Added on weakness today. Can't see these staying at this level for long.

[dougcsv] 17/3/2006 13:45

Perverse market I think....one can hardly say it was already priced in !!

[oscarino] 17/3/2006 09:48

optimum,
thats a bit of an understatement. They were spectacular and yet the share price remains unmoved. ???

[optimum] 16/3/2006 13:44

Good results at Gyrus

[donut114] 09/3/2006 09:08

Osmetech(OMH) gets US clearance for Cystic Fibrosis test

LONDON (AFX) - British diagnostics group Osmetech PLC said US regulators
have cleared its kit that detects the presence of the gene for Cystic Fibrosis,
allowing sales to begin in the first half of the year as planned.
The carrier detection test and its eSensorTM4800 DNA Detection instrument
platform received so-called 510(k) clearance from the US Food & Drug
Administration.
With an incidence of one in 2,500, Cystic Fibrosis is the most commonly
inherited disease in the North American Caucasian population. US medical panels
have recommended that Cystic Fibrosis carrier testing should be made available
for all reproductive couples.
Currently around one million tests are carried out annually in the US alone,
according to Osmetech.
Chief executive James White said in a statement: "Gaining FDA clearance for
our first microarray based test developed for our new eSensor molecular
diagnostics instrument is a major step forward for our Molecular Diagnostics
Division and will help to establish Osmetech as a key player in the fast growing
molecular diagnostics market."
It will also help validate the microarray technology for routine use in the
laboratory, he said.
Talks with strategic partners to work on other complex assays both in the
healthcare and non healthcare markets will now begin.
At 9.35 am AIM-listed Osmetech shares were trading 5 pence, or 16 pct higher
at 35.5, valuing the company at 47 mln stg.

[rochdae] 24/2/2006 16:20

What was that all about!

Lot's of large trades going through.

[joycey2] 16/2/2006 12:36

Anybody got any interesting news to report, if the chart pattern continues looks like another lift is due soon.

[dougcsv] 25/1/2006 08:35

spurrier - do you mean gyg or gyr ?

[spurrier] 20/1/2006 14:31

New to the board.
I just noticed today that my investment in the Rathbone Special Situations fund added GYR to their portfolio sometime in December - some 1.5% of their total fund. Looks to have been good timing.

[woodpecker25] 20/1/2006 09:59

Good write up in the IC this morning. Don't have it to hand I'm afraid but nicely bullish .... mentions a possible upwards re-rating of the share price to come.

[maddox] 20/1/2006 01:19

Thanks Johnroger,

Good to see that GYG is getting coverage from some new quarters. The upward trend has been so steady and consistent that it has largely escaped comment.

Regards, Maddox

[johnroger] 19/1/2006 16:51

Maddox - it was the Indy. Nice to see the price above £4

[johnroger] 18/1/2006 15:25

One of the daily papers on line version -The Times I think but not 100%
Thought it was worth posting for a reasonably balanced view.

[maddox] 17/1/2006 20:42

Thanks for the cutting JohnRoger, what is the publication?

Regards, Maddox

[johnroger] 17/1/2006 15:41

The Investment Column: Gyrus has the scope to pay off long-term

Edited by Julia Kollewe
Published: 17 January 2006
Last year's acquisition of a US rival catapulted Gyrus, hitherto a relatively unknown medical devices company, into the UK's number 2 spot behind Smith & Nephew. Gyrus, a specialist in making equipment for keyhole surgery, had been flirting with American Cystoscope Makers Inc (ACMI) for more than five years and finally tied the knot in June.

Since the start of the millennium, Gyrus has doubled in size three times, each time by well-executed acquisitions. Yesterday's trading update painted a rosy picture for the Cardiff-based group, with the core business growing revenues by 14 per cent last year and ACMI performing well. Overall, annual revenues are expected to total £149m, up 70 per cent from the previous year. City analysts took heart from the fact that the integration of ACMI is proceeding well and upgraded their profit forecasts.

The company certainly paid a racy price - $497m (£280m) - for ACMI, which develops tiny cameras that allow surgeons to see inside the body during operations. It funded the deal through the issue of new equity and by taking on additional debt. But the transformational deal should prove its worth soon as it brings Gyrus the opportunity to move beyond its areas of specialist surgery into the much bigger market for general surgery.

The transaction has married the UK company's high-frequency tissue-cutting and sealing technology with ACMI's new digital endoscope, a camera that can be threaded into the human body. It also gives Gyrus a solid US platform from which to tackle the world's largest surgery market. The synergies are obvious as both companies operate in urology and gynaecology, with Gyrus hoping for sizeable cost savings as it can tap into ACMI's salesforce.

The shares have far outperformed the health sector over the past year, but despite this strong run, we believe they have further to go in the long term. Aside from Gyrus's growth opportunities, the prospect of new North American investors should support the stock going forward. At 385p, the shares are a buy.


.

[rochdae] 17/1/2006 12:07

Nice reaction today. More to come should we break 400

[maddox] 17/1/2006 10:21

These results are great news. It is the first confirmation of the rumours that Gyrus is doing well on two fronts:

>> The major acquisition of ACMI is proceeding well; and

>> Business growth has continued despite this.

It signals that the integration risk is disappearing and the business is set fair to continue on its forward growth.

This period has undoudedly been a terrific test of the management team's metal. Besides the integration effort and keeping the business growth on course they will have been the distraction of establishing their own role in the combined organisation.

The share price should now reflect this change and the confidence one can take in Gyrus' future development.

Regards, Maddox

[johnroger] 16/1/2006 12:22

Gyrus was also in demand, up 10-3/4 pence to 384-3/4, after the medical devices group said in a pre-close period statement that it expects underlying sales growth in the year to Dec 31, 2005, of just over 14 pct to about 100 mln stg.

Panmure Gordon upgraded the shares to 'buy' from 'hold' with a raised target of 398 pence from 358.

Can I second the request for charts or a new thread for 2006

[rochdae] 16/1/2006 08:56

Yes, I expect this will send it through 400. And much more to come by the sound of it.

[gre] 16/1/2006 07:51

Great trading update this morning with earnings predicted to be "towards the higher end of analysts'expectations." Should give the share price another boost.

[woodpecker25] 13/1/2006 11:19

can we have the daily and monthly charts at the top of the page please?
tia

[maddox] 03/12/2005 00:36

Another very strong days trading, up 14p to a new closing high at 370p on high volume. Still escaping market comment. As well as Gyrus' own strengths a couple of other factors might be helping sentiment such as the strengthening dollar and Smith & Nephew attracting investor attention.

However, it is evident that the liquidity of Gyrus has increased substantially since joining the FT250. The X-trades suggest tight stock positions and any demand is immediately being translated into price escalation. It is significant that this is occurring without, a retail fan club, or market commentary. A higher profile for Gyrus' attractions could only add further strength to this momentum.

Regards, Maddox

[maddox] 28/11/2005 23:33

woody33,

Probably market rumours that Gyrus is trading well, see Rafieh's posting 54 above.

Regards, Maddox